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PDB2
A RETROSPECTIVE COHORT STUDY OF
DIABETES MELLITUS AND ANTIPSYCHOTIC
TREATMENT IN THE UNITED KINGDOM
Cavazzoni P1, Hornbuckle K1,Wu J2, Breier A1, Kotsanos J1,
Holman R3
1Lilly Research Laboratories, Indianapolis, IN, USA; 2University
of Michigan, Ann Arbor, MI, USA; 3University of Oxford,
Oxford, Oxford, UK
OBJECTIVE: In this retrospective cohort study, we
explored the UK General Practice Research database
(GPRD) to determine the hazard ratio of diabetes melli-
tus (DM) for patients prescribed antipsychotics compared
with the GPRD general patient population in the UK.
METHODS: An antipsychotic cohort comprised of
patients exposed to both conventional and atypical
antipsychotics (N = 46,111), individual antipsychotic
cohorts comprised of patients exposed to a single antipsy-
chotic, and a general patient population cohort (N =
266,272) derived from the GPRD database were studied.
A Cox proportional hazard regression model was used to
determine the hazard ratio (HR) of diabetes development
between these cohorts. The covariates included in the
model were age, gender, and the presence or absence of
obesity.
RESULTS: Compared to the GPRD general patient 
population cohort, patients exposed to antipsychotics
had a higher risk of developing diabetes (HR = 1.5; CI =
1.1–1.9). The risk of developing diabetes during exposure
to thioridazine and risperidone was signiﬁcantly higher
than that of the GPRD general patient population. Assess-
ment of other antipsychotics was limited by sample size
of the cohorts.
CONCLUSIONS: Patients exposed to antipsychotic
drugs have an increased risk of developing diabetes. 
It remains unclear to what extent the increased risk of
diabetes is related to treatment factors or factors related
to the underlying psychiatric conditions commonly
treated with antipsychotic drugs.
PDB3
IMPROVEMENTS IN LIFE EXPECTANCY WITH
LIFESTYLE CHANGES OR METFORMIN IN
OVERWEIGHT, GLUCOSE INTOLERANT
PATIENTS:A MODELING STUDY OF THE LONG-
TERM IMPLICATIONS OF THE DIABETES
PREVENTION PROGRAM
Palmer AJ1, Roze S
1CORE Center for Outcomes Research, Basel, BS, Switzerland
OBJECTIVES: The Diabetes Prevention Program (DPP)
investigated the effects of intensive lifestyle changes (LsC)
or metformin (MET) on delaying the onset of type 2 
diabetes in overweight patients with impaired glucose 
tolerance (IGT). Patients randomized to either LsC or
MET 850mg twice daily reduced their risk of developing
type 2 diabetes by 58% and 31% respectively, compared
to controls. A simulation model was developed to explore
the long-term implications of delaying onset of type 2 
diabetes with LsC or MET.
METHODS: A Markov model combined data from DPP
with published data on mortality of IGT patients com-
pared to type 2 diabetes, in order to calculate the pos-
sible long-term effects of delaying the onset of diabetes
with LsC or MET on life expectancy (LE). The model
simulated 3 states. “IGT”, “type 2 diabetes”, and “dead”.
Annual transition probabilities for each treatment arm
were derived from the DPP, population studies, and
national mortality statistics. LE was calculated for each
treatment arm. Different assumptions were tested regard-
ing the post-trial effect of the delay of onset of diabetes.
Additional sensitivity analysis was performed to identify
other parameters with important impacts on LE.
RESULTS: Using the conservative assumption, LE from
baseline age of 51 years was 22.95, 23.12, and 23.03
years for the control, LsC, and MET groups respectively.
Using the optimistic assumption, LE further improved by
0.39 and 0.14 years for the LsC and MET groups respec-
tively. Other parameters with important impacts on LE
were the mortality rates in the states of “IGT” and “type
2 diabetes”.
CONCLUSIONS: Interventions that delay the onset of
type 2 diabetes in overweight IGT patients may lead to
important improvements in LE.
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OUTCOMES WITH ROSIGLITAZONE IN
CLINICAL PRACTICE
McGibbon A1,Tuttle J1, Kim T2, Ur E1
1Dalhousie University, Halifax, NS, Canada; 2GlaxoSmithKline,
Mississauga, ON, Canada
OBJECTIVES: Unlike older agents, rosiglitazone lowers
blood glucose levels by directly acting on insulin resis-
tance, the primary metabolic defect of type 2 diabetes,
and has other positive metabolic effects on lipids and
blood pressure. Outcomes of patients on rosiglitazone
used as combination and monotherapy in routine 
Canadian clinical practice is reported.
METHODS: Five Canadian centers participated in retro-
spective data collection. Charts were reviewed for over
635 patients on rosiglitazone with the use of a software
program designed to track outcomes pre and post
Avandia treatment such as glycemic control, metabolic
parameters (including renal function, liver enzymes, 
and lipids) as well as weight, blood pressure and changes
in diabetic medications. Patient data were entered into 
the software and analyzed using standard statistical
methodology.
RESULTS: In the analysis of 337 patients on rosiglita-
zone, the average age was 71.6 years with 44% females.
Rosiglitazone was started as additional therapy to sulpho-
nylureas (38%) or metformin (42%) or both (33.5%).
There were 150 patients on rosiglitazone as monotherapy
(44%). The relative reduction in HbA1c was 15.3% at
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best and 12% at end. Changes in renal function and 
liver enzymes were not statistically signiﬁcant. There was
a signiﬁcant improvement in LDL and blood pressure
while on rosiglitazone. There were eight patients with ele-
vations of liver enzymes.
CONCLUSIONS: In routine Canadian clinical practice,
rosiglitazone is effective at lowering both FBG and
HbA1c signiﬁcantly over time and appear to be compa-
rable to, or better than, those reported for the established
oral agents. Many patients were able to reach improved
targets of HbA1c and FBG with no reported serious
adverse events. Further study is required to investigate the
beneﬁcial metabolic effects observed on blood pressure
and lipids.
DIABETES—Economic Outcomes Presentations
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THE ECONOMIC VALUE OF NON-
DIHYDROPYRIDINE VS. DIHYDROPYRIDINE
CALCIUM CHANNEL BLOCKER/ACE INHIBITOR
COMBINATIONS IN PATIENTS WITH TYPE-II
DIABETES
Keuffel EL1, Cifaldi M2, Botteman MF3
1HERQuLES, Abt Associates Clinical Trials, Cambridge, MA,
USA; 2Abbott Laboratories, Abbott Park, IL, USA; 3Abt
Associates Clinical Trials, Bethesda, MD, USA
OBJECTIVE: Combination therapy with angiotensin-
converting enzyme inhibitors (ACE-I)/calcium channel
blocker (CCB) has been recommended for hypertensive
diabetics. This study assessed the cost-effectiveness of 
an ACE-I/non-dihydropyridine CCB (ACE-I/NDCCB:
Trandolapril/Verapamil or T/V) relative to an ACE-
I/dihydropyridine CCB (ACE-I/DCCB: Benazepril/
Amlodipine or B/A) for the treatment of patients with dia-
betes, who frequently also have hypertension.
METHODS: We have adapted a previously published
Markov model that simulated the disease progression of
a hypothetical cohort newly-diagnosed diabetes patients
towards end-stage renal disease (ESRD). The model was
developed from a payer perspective and estimated the dis-
counted drug and ESRD costs and quality adjusted life
years (QALYs) over a 3-year, 5-year and lifetime time
horizon. The baseline analysis conservatively assumed
that all patients, regardless of treatment received, pro-
gressed from normoalbuminuria to microalbuminuria
(progression rate = 0.011), to gross proteinuria (progres-
sion rate = 0.026), and to ESRD (progression rate =
0.034). Given clinical evidence demonstrating greater
reductions in baseline proteinuria with T/V than with B/A
(urinary albumin excretion -65% versus -25%, respec-
tively), the least conservative scenario assumed that
patients receiving T/V would progress less rapidly than
patients receiving B/A.
RESULTS: In the baseline analysis, T/V resulted in lower
net costs than B/A. The cost advantage per hypertensive
diabetic is $92, $141 and $743 in favor of T/V over a
three-year, ﬁve-year and lifetime time frame respectively.
When the most extreme clinical difference is assumed,
T/V treatment results in $168, $313 and $2,293 in net
savings per diabetic over the respective time periods while
also providing a small net beneﬁt in QALYs (.000632,
.0018, .063 QALYs per patient).
CONCLUSIONS: From a payer perspective, T/V is cost-
saving relative to B/A for the management of hyperten-
sives with diabetes under both scenarios. These savings
are driven by the lower cost of drug and the reduced
resources required for ESRD treatment.
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PREVENTION OF TYPE 2 DIABETES IN THE
USA: COST-EFFECTIVENESS ISSUES
Palmer AJ , Roze S
CORE Center for Outcomes Research, Basel, BS, Switzerland
OBJECTIVES: Onset of Type 2 diabetes (T2D) can be
delayed by lifestyle changes and/or medications. Forecasts
predict an epidemic of new cases of T2D as the popula-
tion ages, and modern lifestyles become increasingly
unhealthy. T2D patients have >double mortality rates and
higher treatment costs of matched non-diabetics. A model
was developed to assess acceptable cost limits for a gen-
eral population-targeted program aimed at reducing the
incidence of T2D by 10%.
METHODS: A Markov model simulated the incidence of
and increased direct medical costs and mortality associ-
ated with T2D. Data were derived from published
sources. Costs and life expectancy (LE) calculated (dis-
counted at 3% p.a.). Analyses assessed the maximum
costs/person a payer could outlay to achieve a 10% reduc-
tion in T2D incidence a) without increasing the health-
care budget, and b) remaining within an attractive
incremental cost-effectiveness (ICER) <$50,000/life year
gained. A health insurance perspective was taken. 
Sensitivity analysis identiﬁed parameters with important
impacts on outcomes.
RESULTS: A diabetes prevention intervention aimed at a
general population with mean age 50 years that reduces
incidence of T2D by 10% would improve LE by 0.05
years per person. Up to a cost of $55/year/person, the
program would result in overall cost savings due avoid-
ance of higher costs associated with T2D. The ICER 
of the program would be <$50,000 at a cost of
$250/person/year. Sensitivity analysis revealed that age of
target population, effectiveness of intervention, incidence
of diabetes, and increase in mortality with diabetes have
a large inﬂuence on the results.
CONCLUSIONS: Diabetes prevention programs aimed
at a general population could be cost saving or cost-
effective if the costs of the program do not exceed limits
identiﬁed. In other, higher-risk populations, such as
glucose intolerant or racial sub-groups, where the inci-
dence of diabetes and effects of intervention are greater,
these cost limits are could be higher.
